secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950170-22-017392
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira reports Q2 net loss $24.3M; ACT-AD Phase 2 Alzheimer's trial missed primary endpoint
--------------------------------------------------------------------------------

- Net loss $24.3M ($0.65/share) vs $14.0M ($0.38/share) in Q2 2021; cash $282.2M.
- ACT-AD Phase 2 trial of fosgonimeton did not meet primary endpoint (P300 latency).
- Monotherapy subgroup showed ADAS-Cog11 improvement of -3.3 points vs placebo (not significant).
- Statistically significant reduction in plasma NfL biomarker in monotherapy subgroup (p=0.018).
- LIFT-AD Phase 3 enrollment ongoing; over 300 patients enrolled as of report date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022017392/0000950170-22-017392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022017392/atha-20220815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer